# Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Phase 1 study started recruiting, 27 planned (Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)))

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Sponsor type | Academic and hospital |
| Study | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) |
| NCT ID | NCT07430202 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) |
| Intervention types | drug |
| Target enrollment | 27 |
| Site countries | United States |
| Posted | 2026-02-24 |
| Planned start | 2026-10-28 |
| Event | Started recruiting |
| Event date | 2026-10-28 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Just started recruiting: sites, recruitment and supply are active.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07430202). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.